CN116350712B - Traditional Chinese medicine composition for treating polycystic ovarian syndrome and application thereof - Google Patents
Traditional Chinese medicine composition for treating polycystic ovarian syndrome and application thereof Download PDFInfo
- Publication number
- CN116350712B CN116350712B CN202310539564.1A CN202310539564A CN116350712B CN 116350712 B CN116350712 B CN 116350712B CN 202310539564 A CN202310539564 A CN 202310539564A CN 116350712 B CN116350712 B CN 116350712B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 206010036049 Polycystic ovaries Diseases 0.000 title description 4
- 210000000582 semen Anatomy 0.000 claims abstract description 16
- 241000218671 Ephedra Species 0.000 claims abstract description 8
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 7
- 241000132012 Atractylodes Species 0.000 claims abstract description 7
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 7
- 241000234435 Lilium Species 0.000 claims abstract description 7
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 7
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 6
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 6
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 6
- 235000011477 liquorice Nutrition 0.000 claims abstract description 6
- 241000735527 Eupatorium Species 0.000 claims abstract description 5
- 241000207925 Leonurus Species 0.000 claims abstract description 5
- 240000001949 Taraxacum officinale Species 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 235000006463 Brassica alba Nutrition 0.000 claims description 5
- 244000140786 Brassica hirta Species 0.000 claims description 5
- 235000011371 Brassica hirta Nutrition 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 4
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims description 2
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 8
- 208000000509 infertility Diseases 0.000 abstract description 6
- 231100000535 infertility Toxicity 0.000 abstract description 6
- 230000036512 infertility Effects 0.000 abstract description 6
- 230000035935 pregnancy Effects 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 14
- 239000000463 material Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000000284 extract Substances 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 3
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 241000245665 Taraxacum Species 0.000 description 3
- 229960003473 androstanolone Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 208000030941 fetal growth restriction Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002262 irrigation Effects 0.000 description 3
- 238000003973 irrigation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000220261 Sinapis Species 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000006371 metabolic abnormality Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 208000015994 miscarriage Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000308663 Eupatorium fortunei Species 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 201000010272 acanthosis nigricans Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 201000010066 hyperandrogenism Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Zoology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating polycystic ovary syndrome and application thereof, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises the following components in parts by weight: 10-14 parts of cornu cervi degelatinatum, 13-17 parts of semen cuscutae, 4-8 parts of fried semen brassicae, 4-8 parts of roasted ephedra, 10-14 parts of platycodon grandiflorum, 7-11 parts of dandelion, 7-11 parts of honeysuckle, 10-14 parts of eupatorium, 10-14 parts of radix angelicae, 10-14 parts of lily, 10-14 parts of caulis perllae, 10-14 parts of leonurus, 10-14 parts of fried bighead atractylodes rhizome, 10-14 parts of radix cyathulae and 4-8 parts of raw liquorice. The traditional Chinese medicine composition provided by the invention can effectively treat polycystic ovary syndrome, and particularly has a good treatment effect on patients with infertility or bad pregnancy history.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating polycystic ovary syndrome and application thereof.
Background
Polycystic ovary syndrome (polycystic ovarian syndrome, PCOS) is a disorder characterized by hyperandrogenism, anovulation disorders, and polycystic ovary. The etiology of polycystic ovary syndrome is not completely clear, but mainly uses insulin resistance as a main related factor, and also comprises genetic factors and non-genetic factors, and the pathophysiology of polycystic ovary syndrome is mainly caused by metabolic disorder caused by insulin resistance and endocrine change caused by hypothalamic-pituitary-ovary axis regulation dysfunction. The disease has highly heterogeneous clinical syndrome, and different patients have different physiological and pathological manifestations. The clinical characteristics of the medicine are as follows: menstrual disorder, infertility, male sexual manifestations (hirsutism, acne), obesity, acanthosis nigricans, increased ovaries, endocrine changes (elevated androgen levels, altered estrogen, gonadotrophin changes, insulin resistance, hyperinsulinemia, elevated serum prolactin levels), long-term complications (tumors, cardiovascular diseases, diabetes).
Polycystic ovary syndrome is the most common endocrine and metabolic disorder in women, with a morbidity of 5-10%. PCOS is mainly pathophysiologically changed into a reproductive disorder and a metabolic abnormality, and the occurrence and development of the disease and clinical symptoms cover the life of women, and seriously affect the reproductive health and population quality of human beings. PCOS patients manifest themselves as intrauterine growth restriction (IUGR) in fetal phase leading to reduced birth weight; the phenomenon of weight catch-up occurs in childhood, which is a high-frequency population with overweight, obesity and menstrual disorder in adolescent girls; during the growth period, the main symptoms are amenorrhea and infertility, and the metabolic abnormality is mainly manifested by impaired glucose tolerance, abnormal lipid metabolism and the like; once pregnant, the incidence rate of gestational diabetes mellitus and gestational hypertension disease is increased by 5-10 times, and the IUGR of the intrauterine fetus is obviously increased; the probability of occurrence of diabetes, hypertension, cardiovascular and cerebrovascular diseases and other chronic diseases before and after menopause is increased by more than 4 times compared with normal women. PCOS has gradually been considered as an important component of metabolic syndrome due to its high incidence in women at different physiological stages. However, due to the unclear etiology, the treatment of PCOS by western medicine is stagnated in the stage of symptomatic treatment, and all the problems of patients cannot be completely solved, and adverse reactions of a large amount of long-time use of chemical medicaments and high heterogeneity of PCOS lead to complicated treatment for the disease, and most of the treatments are symptomatic treatment, rebound easily occurs after stopping the treatment, and the disease development is aggravated. The traditional Chinese medicine for preventing and treating PCOS has unique advantages, is now increasingly valued and accepted by the medical community, and has more reports on the traditional Chinese medicine for preventing and treating PCOS, but only treats diseases per se, or treats certain types or stages, has limited indications, is difficult to treat clinically, and needs to develop a traditional Chinese medicine composition with wide indications, so that the treatment effect on PCOS patients, especially PCOS patients with infertility or bad pregnancy history is improved.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating polycystic ovary syndrome and application thereof, so as to solve the problems of the prior art.
In order to achieve the above object, the present invention provides the following solutions:
the invention provides a traditional Chinese medicine composition for treating polycystic ovary syndrome, which comprises the following components in parts by weight: 10-14 parts of cornu cervi degelatinatum, 13-17 parts of semen cuscutae, 4-8 parts of fried semen brassicae, 4-8 parts of roasted ephedra, 10-14 parts of platycodon grandiflorum, 7-11 parts of dandelion, 7-11 parts of honeysuckle, 10-14 parts of eupatorium, 10-14 parts of radix angelicae, 10-14 parts of lily, 10-14 parts of caulis perllae, 10-14 parts of leonurus, 10-14 parts of fried bighead atractylodes rhizome, 10-14 parts of radix cyathulae and 4-8 parts of raw liquorice.
Preferably, the traditional Chinese medicine composition comprises the following components in parts by weight: 12 parts of cornu cervi degelatinatum, 15 parts of semen cuscutae, 6 parts of stir-fried white mustard seed, 6 parts of roasted ephedra, 12 parts of platycodon grandiflorum, 9 parts of dandelion, 9 parts of honeysuckle, 12 parts of eupatorium, 12 parts of radix angelicae, 12 parts of lily, 12 parts of caulis perllae, 12 parts of motherwort, 12 parts of stir-fried bighead atractylodes rhizome, 12 parts of radix cyathulae and 6 parts of raw liquorice.
The invention also provides application of the traditional Chinese medicine composition in preparing medicines for treating polycystic ovary syndrome.
The invention also provides a medicine for treating polycystic ovary syndrome, and the raw materials comprise the traditional Chinese medicine composition.
Further, the medicament also comprises pharmaceutically acceptable auxiliary materials.
Further, the dosage form of the medicament comprises powder, pill, granule, paste or tablet.
The invention also provides a preparation method of the medicine, which comprises the steps of extracting the active ingredients in the traditional Chinese medicine composition by using a solvent and preparing the medicine.
Further, the solvent includes water.
The invention discloses the following technical effects:
in the traditional Chinese medicine composition of the invention: cornu Cervi Degelatinatum is salty, astringent, warm, and enters liver and kidney meridians to warm kidney and strengthen yang, and is a monarch drug. Semen cuscutae is sweet and warm, enters liver, kidney and spleen channels, nourishes liver and kidney, arrest semen, prevent abortion and improve eyesight; the fried white atractylodes rhizome is sweet and warm, has the functions of invigorating spleen and stomach meridian, strengthening spleen and replenishing qi, drying dampness and promoting diuresis, and preventing miscarriage; the stir-fried white mustard seed is pungent and warm, enters lung and stomach meridians, promotes qi circulation and eliminates phlegm, warms middle-jiao and dispels cold, and relieves pain, and the three medicines are ministerial medicines. Dandelion has the effects of clearing heat and detoxicating, eliminating carbuncles and resolving masses, and promoting diuresis and treating stranguria; honeysuckle flower, flos Lonicerae, sweet and cold, enters the lung, heart and stomach meridians, and clears away heat and toxic materials; the roasted ephedra can ventilate the lung and promote diuresis; radix angelicae dehumidifies and promotes tissue regeneration, and activates blood circulation to relieve pain; herba Leonuri has effects of promoting blood circulation, removing blood stasis, detumescence and resolving hard mass; radix Platycodi has effects of dispersing lung qi, relieving sore throat, eliminating phlegm, and expelling pus; herba Eupatorii fragrance for eliminating dampness; lily is sweet in taste and cold in nature, and can return to heart and lung channels, nourish yin and clear heart, calm heart and tranquilize mind; caulis Perillae is pungent and sweet, slightly warm, and has effects of invigorating lung, spleen and stomach channels, relieving chest stuffiness, benefiting diaphragm, regulating qi and preventing miscarriage; radix Cyathulae is bitter, sweet and sour, and has effects of calming liver, invigorating kidney, promoting blood circulation, dredging channels, nourishing liver and kidney, strengthening tendons and bones, guiding drugs downwards, and the ten drugs are adjuvant drugs. The raw licorice is sweet and flat, enters heart, lung, spleen and stomach meridians, supplements qi and supplements middle-jiao, clears away heat and toxic materials, eliminates phlegm and relieves cough, relieves spasm and pain, and harmonizes drug properties, thus being a guiding drug. The medicines are combined together to play the roles of nourishing liver and kidney, strengthening spleen and nourishing heart, resolving phlegm and removing dampness, promoting blood circulation and regulating menstruation.
The mouse experiment proves that the traditional Chinese medicine composition can effectively treat polycystic ovary syndrome, and particularly has a good treatment effect on patients with infertility or bad gestation history.
Detailed Description
Various exemplary embodiments of the invention will now be described in detail, which should not be considered as limiting the invention, but rather as more detailed descriptions of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. In addition, for numerical ranges in this disclosure, it is understood that each intermediate value between the upper and lower limits of the ranges is also specifically disclosed. Every smaller range between any stated value or stated range, and any other stated value or intermediate value within the stated range, is also encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the invention described herein without departing from the scope or spirit of the invention. Other embodiments will be apparent to those skilled in the art from consideration of the specification of the present invention. The specification and examples of the present invention are exemplary only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are intended to be inclusive and mean an inclusion, but not limited to.
Example 1
Raw materials: ( First ) 10g of cornu cervi degelatinatum, 17g of semen cuscutae, 4g of fried semen brassicae, 8g of roasted ephedra, 10g of platycodon grandiflorum, 7g of dandelion, 11g of honeysuckle, 14g of eupatorium fortunei, 10g of radix angelicae, 10g of lily, 10g of caulis perllae, 14g of leonurus, 14g of fried bighead atractylodes rhizome, 14g of radix cyathulae and 8g of raw liquorice.
The preparation method comprises the following steps: soaking the above materials in water, decocting cornu Cervi Degelatinatum for 30min, adding the rest materials, decocting for 2 times and 25 min each time, mixing decoctions, filtering, and drying to obtain Chinese medicinal extract.
Example 2
Raw materials: cornu Cervi Degelatinatum ( First ) g, semen Cuscutae 15g, semen Sinapis Albae preparata 6g, herba Ephedrae preparata 6g, radix Platycodi 12g, herba Taraxaci 9g, flos Lonicerae 9g, herba Eupatorii 12g, radix Angelicae Dahuricae 12g, bulbus Lilii 12g, caulis Perillae 12g, herba Leonuri 12g, atractylodis rhizoma 12g, radix Cyathulae 12g and Glycyrrhrizae radix 6g.
The preparation method comprises the following steps: the preparation method comprises the following steps: soaking the above materials in water, decocting cornu Cervi Degelatinatum for 30min, adding the rest materials, decocting for 2 times and 25 min each time, mixing decoctions, filtering, and drying to obtain Chinese medicinal extract.
Example 3
Raw materials: cornu Cervi Degelatinatum ( First ) g, semen Cuscutae 13g, semen Sinapis Albae 8g, herba Ephedrae preparata 4g, radix Platycodi 14g, herba Taraxaci 11g, flos Lonicerae 7g, herba Eupatorii 10g, radix Angelicae Dahuricae 14g, bulbus Lilii 14g, caulis Perillae 14g, herba Leonuri 10g, atractylodis rhizoma 10g, radix Cyathulae 10g and Glycyrrhrizae radix 4g.
The preparation method comprises the following steps: the preparation method comprises the following steps: soaking the above materials in water, decocting cornu Cervi Degelatinatum for 30min, adding the rest materials, decocting for 2 times and 25 min each time, mixing decoctions, filtering, and drying to obtain Chinese medicinal extract.
Comparative example 1
The only difference from example 2 is that the stir-fried white mustard seeds are replaced with raw white mustard seeds.
Comparative example 2
The only difference from example 2 is that the roasted ephedra is replaced with cassia twig.
Comparative example 3
The only difference from example 2 is that the herba Eupatorii is replaced with herba Pogostemonis.
Effect verification
1. Method of
C57 mice are purchased from Beijing shellfish organisms, the temperature is 20-24 ℃, the constant humidity is 50-60%, the light is irradiated for 12 hours (8:00-20:00), sound insulation is realized, food and water are freely ingested, and experiments are carried out after one week of adaptation to the environment.
Adult C57 female mice and male mice were caged at 4 PM on the first 1 day, the caged ratio was 2:1, the next morning, and the male mice with the bolts were marked and divided into two groups, which was designated as day 1. Mice in the control group were injected subcutaneously with 200 μl sesame oil daily on the back of the mice 16, 17, 18 days after thrombus formation, mice in the model group were injected subcutaneously with 200 μl of DHT (dihydrotestosterone) containing sesame oil daily on the back of the mice (DHT amount was 250 μg) and the injection was continued for 3 days. After 2 months, ovaries of offspring females were collected, fixed with 4% paraformaldehyde for 48 hours, rinsed with running water for 6 hours, embedded, HE stained and the ovaries were observed under a microscope. The results showed that the model group offspring adult female ovaries presented multiple sacs compared to the control group, indicating that PCOS mouse model construction was successful.
140 PCOS mice were taken and randomly divided into 7 groups of 20 mice each. Wherein 6 groups were respectively subjected to stomach irrigation with the extracts of the traditional Chinese medicines prepared in examples 1-3 and comparative examples 1-3 (diluted in water for stomach irrigation), and the stomach irrigation amount was 10 mg/kg/d; the other 1 group was used as a model control group, and the same volume of water was used in place of the herbal extract. Then, 20 normal C57 female mice were taken as normal control group.
Each experimental group was continuously dosed for 4 weeks, after the last dose, normal feed and drinking water were given, 4 male mice in physiological maturity stage were added to each group, and the number of pregnant females and the parity of each group were counted after 2 months.
2. Results
TABLE 1
Note that: * Significant P <0.05 from normal control group; # Significant P <0.05 from the model control group was indicated.
The results show that the number of pregnant female mice and parity in the model control group is obviously lower than that in the normal control group; after the traditional Chinese medicine extract is taken, although the traditional Chinese medicine extract still has certain difference from a normal control group, the number of pregnant female mice and parity animals is obviously improved. Therefore, the traditional Chinese medicine composition can treat polycystic ovary syndrome, and has good treatment effect on patients with infertility or bad pregnancy history.
The above embodiments are only illustrative of the preferred embodiments of the present invention and are not intended to limit the scope of the present invention, and various modifications and improvements made by those skilled in the art to the technical solutions of the present invention should fall within the protection scope defined by the claims of the present invention without departing from the design spirit of the present invention.
Claims (8)
1. The traditional Chinese medicine composition for treating polycystic ovary syndrome is characterized by being prepared from the following components in parts by weight: 10-14 parts of cornu cervi degelatinatum, 13-17 parts of semen cuscutae, 4-8 parts of fried semen brassicae, 4-8 parts of roasted ephedra, 10-14 parts of platycodon grandiflorum, 7-11 parts of dandelion, 7-11 parts of honeysuckle, 10-14 parts of eupatorium, 10-14 parts of radix angelicae, 10-14 parts of lily, 10-14 parts of caulis perllae, 10-14 parts of leonurus, 10-14 parts of fried bighead atractylodes rhizome, 10-14 parts of radix cyathulae and 4-8 parts of raw liquorice.
2. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following components in parts by weight: 12 parts of cornu cervi degelatinatum, 15 parts of semen cuscutae, 6 parts of stir-fried white mustard seed, 6 parts of roasted ephedra, 12 parts of platycodon grandiflorum, 9 parts of dandelion, 9 parts of honeysuckle, 12 parts of eupatorium, 12 parts of radix angelicae, 12 parts of lily, 12 parts of caulis perllae, 12 parts of motherwort, 12 parts of stir-fried bighead atractylodes rhizome, 12 parts of radix cyathulae and 6 parts of raw liquorice.
3. Use of a traditional Chinese medicine composition according to claim 1 or 2 for preparing a medicament for treating polycystic ovary syndrome.
4. A medicament for treating polycystic ovary syndrome, which is characterized in that raw materials comprise the traditional Chinese medicine composition as claimed in claim 1 or 2.
5. The medicament of claim 4, further comprising a pharmaceutically acceptable excipient.
6. The medicament according to claim 5, wherein the dosage form of the medicament comprises a powder, a pill, a granule, a paste or a tablet.
7. The method for preparing a medicament according to claim 4, which comprises the step of extracting the active ingredient of the Chinese medicinal composition according to claim 1 or 2 with a solvent and preparing the medicament.
8. The method of claim 7, wherein the solvent comprises water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310539564.1A CN116350712B (en) | 2023-05-15 | 2023-05-15 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310539564.1A CN116350712B (en) | 2023-05-15 | 2023-05-15 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116350712A CN116350712A (en) | 2023-06-30 |
| CN116350712B true CN116350712B (en) | 2024-04-16 |
Family
ID=86909560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310539564.1A Active CN116350712B (en) | 2023-05-15 | 2023-05-15 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116350712B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491295A (en) * | 2015-01-17 | 2015-04-08 | 河南中医学院 | Traditional Chinese medicine composition used for treating polycystic ovarian syndrome |
-
2023
- 2023-05-15 CN CN202310539564.1A patent/CN116350712B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491295A (en) * | 2015-01-17 | 2015-04-08 | 河南中医学院 | Traditional Chinese medicine composition used for treating polycystic ovarian syndrome |
Non-Patent Citations (1)
| Title |
|---|
| 青春期闭经25例临床观察;曾真;上海中医药杂志;-(第11期);22-23 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116350712A (en) | 2023-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104352804B (en) | Dendrobium candidum compound preparation with kidney invigorating and Yang strengthening function and its preparation method and application | |
| CN101095825A (en) | Chinese patent drug for treating mammary gland hyperplasia and mammitis and method for preparing the same | |
| CN103386022B (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN116350712B (en) | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and application thereof | |
| CN101112475A (en) | Chinese traditional medicine composition for treating diabetes and the complication | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN1108159C (en) | Traditional Chinese medicine for curing diabetes and kidney deficiency | |
| CN116570675A (en) | Traditional Chinese medicine for treating respiratory tract virus infection later stage such as new coronaries pneumonia | |
| CN103330867B (en) | Preparation method of powder for treating senile vaginitis | |
| CN1480204A (en) | Preparation of Chinese herbal medicine for treating barrenness of women | |
| CN111789913A (en) | Traditional Chinese medicine compound preparation for treating salpingitis of laying hens and application | |
| CN103721019B (en) | A kind of Chinese medicine composition improving rheumatoid arthritis | |
| CN110237119A (en) | A pharmaceutical composition for treating oral mucosal diseases, its preparation method and application | |
| CN117180353B (en) | A Chinese medicine composition for treating diabetes and its preparation method | |
| CN116920061B (en) | Traditional Chinese medicine composition for treating hyperglycemia and preparation method thereof | |
| KR102692595B1 (en) | Composition for treating and preventing constipation comprising Angelica gigas extract as an active ingredient | |
| CN113521206B (en) | Traditional Chinese medicine composition containing burdock | |
| CN109157617B (en) | A Chinese medicinal composition for treating diabetes | |
| CN102233004B (en) | Drug for treating liver diseases | |
| CN107137633B (en) | A kind of traditional Chinese medicine composition for invigorating kidney and removing turbidity and application | |
| CN119258177A (en) | A Chinese medicine composition for treating chronic prostatitis and its preparation method and application | |
| CN110585268A (en) | Composition for improving male endurance and energy vitality as well as preparation method and application thereof | |
| CN118078943A (en) | Traditional Chinese medicine composition for treating depression by shinyleaf yellowhorn and preparation method thereof | |
| CN1686272A (en) | Medicine for treating chronic prostatitis and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |